NCT04950868

The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression

A Pilot Study on the Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Verinder Sharma · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Postpartum depression is a serious disorder that affects approximately 14% of women who have recently given birth. Postpartum depression is either an episode of major depressive disorder (only low periods) or bipolar disorder (periods of lows and highs). Untreated postpartum depression can negatively affect the mother, the infant and the family. Antidepressants are the most used treatments; however, for many women these drugs are not useful, resulting in a pressing need for effective treatments for postpartum depression. Lack of sleep is common after delivery and can trigger depression in some women. Quetiapine, a drug used for bipolar disorder, major depressive disorder and occasionally sleeplessness has not been well studied in postpartum depression. This study aims to find out how mothers tolerate the drug and whether it is effective for postpartum depression. Results of this study may help investigators carry out a larger study comparing quetiapine and placebo (a sugar pill) in postpartum depression.

Conditions

• Postpartum Depression

Interventions

Type	Name	Description
DRUG	Quetiapine	They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.

Timeline

• Start date: 2022-03-18
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2021-07-06
• Last updated: 2025-03-05

Locations

1 site across 1 country: Canada